Condition: HLH · Hemophagocytic Lymphohistiocytoses · Hemophagocytic Syndrome · Sponsor: Meir Medical Center
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
This description comes directly from the study's public registry record.
Adi Zoref Lorenz, MD · 513 6525610 · adi.zoref.lorenz@cchmc.org
Noa Rabinowicz, PhD · +972-54-4864564 · noa.rabinowicz@clalit.org.il
Always discuss trial participation with your own doctor first.
| Meir Medical Center | Kfar Saba, Israel | Recruiting |
| Rabin Medical Center | Petah Tikva, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05882175